CL2005002823A1 - Anticuerpos anti-virus respiratorio sincitial, antigenos y usos de los mismos - Google Patents
Anticuerpos anti-virus respiratorio sincitial, antigenos y usos de los mismosInfo
- Publication number
- CL2005002823A1 CL2005002823A1 CL2005002823A CL2005002823A CL2005002823A1 CL 2005002823 A1 CL2005002823 A1 CL 2005002823A1 CL 2005002823 A CL2005002823 A CL 2005002823A CL 2005002823 A CL2005002823 A CL 2005002823A CL 2005002823 A1 CL2005002823 A1 CL 2005002823A1
- Authority
- CL
- Chile
- Prior art keywords
- virus
- antigens
- same
- virus anti
- Prior art date
Links
- 230000002155 anti-virotic effect Effects 0.000 title 3
- 239000000427 antigen Substances 0.000 title 1
- 102000036639 antigens Human genes 0.000 title 1
- 108091007433 antigens Proteins 0.000 title 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/08—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from viruses
- C07K16/10—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from viruses from RNA viruses
- C07K16/1027—Paramyxoviridae, e.g. respiratory syncytial virus
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/12—Viral antigens
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/12—Viral antigens
- A61K39/155—Paramyxoviridae, e.g. parainfluenza virus
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/56—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule
- A61K47/59—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes
- A61K47/60—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes the organic macromolecular compound being a polyoxyalkylene oligomer, polymer or dendrimer, e.g. PEG, PPG, PEO or polyglycerol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
- A61K2039/53—DNA (RNA) vaccination
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/55—Fab or Fab'
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
- C07K2317/565—Complementarity determining region [CDR]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
- C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
- C12N2760/00011—Details
- C12N2760/18011—Paramyxoviridae
- C12N2760/18511—Pneumovirus, e.g. human respiratory syncytial virus
- C12N2760/18522—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
- C12N2760/00011—Details
- C12N2760/18011—Paramyxoviridae
- C12N2760/18511—Pneumovirus, e.g. human respiratory syncytial virus
- C12N2760/18534—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Virology (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Organic Chemistry (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Epidemiology (AREA)
- Immunology (AREA)
- Molecular Biology (AREA)
- Genetics & Genomics (AREA)
- Biophysics (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Biochemistry (AREA)
- Microbiology (AREA)
- Mycology (AREA)
- Pulmonology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Gastroenterology & Hepatology (AREA)
- Oncology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Communicable Diseases (AREA)
- General Chemical & Material Sciences (AREA)
- Peptides Or Proteins (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US62298104P | 2004-10-28 | 2004-10-28 |
Publications (1)
Publication Number | Publication Date |
---|---|
CL2005002823A1 true CL2005002823A1 (es) | 2007-04-20 |
Family
ID=36319746
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CL2005002823A CL2005002823A1 (es) | 2004-10-28 | 2005-10-28 | Anticuerpos anti-virus respiratorio sincitial, antigenos y usos de los mismos |
Country Status (9)
Country | Link |
---|---|
US (2) | US20060159695A1 (es) |
EP (1) | EP1809319A4 (es) |
JP (1) | JP2008518602A (es) |
AR (1) | AR051942A1 (es) |
AU (1) | AU2005302301B2 (es) |
CA (1) | CA2585817A1 (es) |
CL (1) | CL2005002823A1 (es) |
TW (1) | TW200636064A (es) |
WO (1) | WO2006050280A2 (es) |
Families Citing this family (33)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
DE102006060799A1 (de) | 2006-12-21 | 2008-06-26 | RUHR-UNIVERSITäT BOCHUM | RSV F-Protein und seine Verwendung |
US7867497B2 (en) | 2007-09-24 | 2011-01-11 | Vanderbilt University | Monoclonal antibodies to respiratory syncytial virus and uses therefor |
EP2231904B1 (en) | 2007-12-19 | 2016-01-13 | Janssen Biotech, Inc. | Design and generation of human de novo pix phage display libraries via fusion to pix or pvii, vectors, antibodies and methods |
KR100938998B1 (ko) * | 2008-01-08 | 2010-01-28 | (주) 에이프로젠 | 호흡기 신시티움 바이러스에 대한 항체 |
ES2594102T3 (es) * | 2008-04-18 | 2016-12-15 | Vaxinnate Corporation | Mutantes por deleción de la flagelina y métodos para su uso |
PT2285408T (pt) | 2008-06-05 | 2019-02-01 | Ablynx Nv | Sequências de aminoácidos dirigidas contra proteínas de envelope de um vírus e polipéptidos que as compreendem para o tratamento de doenças virais |
JP5575377B2 (ja) * | 2008-07-18 | 2014-08-20 | シスメックス株式会社 | 抗rsウイルスモノクローナル抗体を用いたrsウイルス検出用キット及びイムノクロマトグラフィー用試験具、並びに新規な抗rsウイルスモノクローナル抗体 |
DK2438087T3 (en) * | 2009-06-05 | 2017-08-28 | Ablynx Nv | TRIVALENT NANOBODY CONSTRUCTIONS AGAINST HUMAN RESPIRATORY SYNCYTIAL VIRUS (HRSV) FOR PREVENTION AND / OR TREATMENT OF AIR INFECTIONS |
WO2011020079A1 (en) * | 2009-08-13 | 2011-02-17 | Calmune Corporation | Antibodies against human respiratory syncytial virus (rsv) and methods of use |
US9644022B2 (en) | 2009-11-30 | 2017-05-09 | Ablynx N.V. | Amino acid sequences directed against human respiratory syncytial virus (HRSV) and polypeptides comprising the same for the prevention and/or treatment of respiratory tract infections |
CA3062786C (en) | 2010-07-09 | 2022-04-19 | Janssen Vaccines & Prevention B.V. | Anti-human respiratory syncytial virus (rsv) antibodies and methods of use |
US10047145B2 (en) | 2013-07-24 | 2018-08-14 | Humabs Biomed Sa | Antibodies that potently neutralize RSV and uses thereof |
EP3586871A3 (en) * | 2013-08-21 | 2020-03-11 | CureVac AG | Respiratory syncytial virus (rsv) vaccine |
BR112016003361A2 (pt) * | 2013-08-21 | 2017-11-21 | Curevac Ag | vacina do vírus sincicial respiratório (rsv) |
US9340604B1 (en) * | 2014-10-29 | 2016-05-17 | Aridis Pharmaceuticals, Inc. | Human monoclonal antibody specific for the F protein of respiratory syncytial virus (RSV) |
NL2014935B1 (en) | 2015-06-08 | 2017-02-03 | Applied Immune Tech Ltd | T cell receptor like antibodies having fine specificity. |
JO3555B1 (ar) * | 2015-10-29 | 2020-07-05 | Merck Sharp & Dohme | جسم مضاد يبطل فعالية فيروس الالتهاب الرئوي البشري |
EP3387019B1 (en) * | 2015-12-09 | 2021-10-20 | The Scripps Research Institute | Relaxin immunoglobulin fusion proteins and methods of use |
PE20181354A1 (es) | 2015-12-23 | 2018-08-22 | Pfizer | Mutantes de proteina f de rsv |
EA039222B1 (ru) * | 2016-07-27 | 2021-12-20 | Мерк Шарп И Доум Корп. | Антитело, нейтрализующее респираторно-синцитиальный вирус человека |
US11840565B2 (en) | 2016-12-29 | 2023-12-12 | University Of Miami | Methods and compositions for treating virus-associated inflammation |
RU2019123160A (ru) | 2016-12-29 | 2021-01-29 | Юниверсити Оф Майами | Способ модуляции активности инфламмасом и воспаления в легком |
TWI761453B (zh) | 2017-03-01 | 2022-04-21 | 英商梅迪繆思有限公司 | 抗rsv單株抗體配製物 |
EP3595713A4 (en) | 2017-03-15 | 2021-01-13 | ModernaTX, Inc. | RESPIRATORY SYNCYTIAL VIRUS VACCINE |
MX2019015053A (es) | 2017-06-14 | 2020-02-13 | Adicet Bio Inc | Anticuerpos capaces de unirse a hla-a2/tyrd de forma restringida por hla y usos de estos. |
EP3746090A4 (en) | 2018-01-29 | 2021-11-17 | ModernaTX, Inc. | RSV RNA Vaccines |
JP7371009B2 (ja) * | 2018-04-23 | 2023-10-30 | アメリカ合衆国 | キメラベクター |
CN113316588A (zh) * | 2018-07-03 | 2021-08-27 | 迈阿密大学 | 用于治疗炎性小体相关疾病或病症的组合物和方法 |
US20210198323A1 (en) * | 2018-08-17 | 2021-07-01 | Icahn School Of Medicine At Mount Sinai | Recombinant newcastle disease viruses and uses thereof for the prevention of rsv disease or human metapneumovirus disease |
CN111606992B (zh) * | 2019-02-25 | 2022-08-19 | 天津昊免生物技术有限公司 | 一种抗呼吸道合胞病毒的全人源抗体 |
WO2021202463A1 (en) | 2020-03-30 | 2021-10-07 | Danisco Us Inc | Anti-rsv antibodies |
KR20230066722A (ko) * | 2021-11-08 | 2023-05-16 | 한국생명공학연구원 | 시나지스 내성 호흡기세포융합바이러스 검출 방법 |
CN116987183A (zh) * | 2022-07-22 | 2023-11-03 | 北京智仁美博生物科技有限公司 | 抗呼吸道合胞病毒中和性抗体及其用途 |
Family Cites Families (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4816567A (en) * | 1983-04-08 | 1989-03-28 | Genentech, Inc. | Recombinant immunoglobin preparations |
US5824307A (en) * | 1991-12-23 | 1998-10-20 | Medimmune, Inc. | Human-murine chimeric antibodies against respiratory syncytial virus |
GB9207479D0 (en) * | 1992-04-06 | 1992-05-20 | Scotgen Ltd | Novel antibodies for treatment and prevention of respiratory syncytial virus infection in animals and man |
US5843912A (en) * | 1994-07-06 | 1998-12-01 | Universy Of Maryland | Ring-expanded nucleosides and nucleotides |
US6019980A (en) * | 1995-06-07 | 2000-02-01 | Connaught Laboratories Limited | Nucleic acid respiratory syncytial virus vaccines |
-
2005
- 2005-10-27 TW TW094137584A patent/TW200636064A/zh unknown
- 2005-10-28 JP JP2007539255A patent/JP2008518602A/ja active Pending
- 2005-10-28 AU AU2005302301A patent/AU2005302301B2/en not_active Ceased
- 2005-10-28 CA CA002585817A patent/CA2585817A1/en not_active Abandoned
- 2005-10-28 CL CL2005002823A patent/CL2005002823A1/es unknown
- 2005-10-28 EP EP05820207A patent/EP1809319A4/en not_active Withdrawn
- 2005-10-28 WO PCT/US2005/039299 patent/WO2006050280A2/en active Application Filing
- 2005-10-28 US US11/261,356 patent/US20060159695A1/en not_active Abandoned
- 2005-10-28 AR ARP050104531A patent/AR051942A1/es not_active Application Discontinuation
-
2010
- 2010-10-08 US US12/900,924 patent/US20110027294A1/en not_active Abandoned
Also Published As
Publication number | Publication date |
---|---|
EP1809319A4 (en) | 2009-11-18 |
WO2006050280A2 (en) | 2006-05-11 |
CA2585817A1 (en) | 2006-05-11 |
US20110027294A1 (en) | 2011-02-03 |
JP2008518602A (ja) | 2008-06-05 |
AU2005302301B2 (en) | 2012-08-02 |
EP1809319A2 (en) | 2007-07-25 |
US20060159695A1 (en) | 2006-07-20 |
WO2006050280A3 (en) | 2009-05-14 |
TW200636064A (en) | 2006-10-16 |
AU2005302301A1 (en) | 2006-05-11 |
AR051942A1 (es) | 2007-02-21 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CL2005002823A1 (es) | Anticuerpos anti-virus respiratorio sincitial, antigenos y usos de los mismos | |
CR10709A (es) | Determinadas amidas sustituidas, metodo de elaboracion y metodo de uso de las mismas | |
DK1805312T3 (da) | Fremgangsmåder og midler til fremstilling af hyaluronan | |
NO20023283D0 (no) | Flammestopper | |
DE602005021959D1 (de) | Substituierte diazaspiroä4.5üdecanderivate und der | |
DK1833532T3 (da) | Sikkerhedssprøjte | |
CR10743A (es) | Derivados de azaadamantano y metodos de uso de los mismos | |
ATE461285T1 (de) | Herstellung von tnfr-fc | |
DE602005012267D1 (de) | N von geräten | |
ES2356376T8 (es) | Procedimiento cosmetico para las axilas. | |
DE602004017351D1 (de) | Fft-architektur und -verfahren | |
DE602005012462D1 (de) | Luftdämpfer | |
ITMI20031145A1 (it) | Dispositivo e procedimento di cottura. | |
DE602006006710D1 (de) | Herstellung von polytrimethylenetherglykol und copolymeren davon | |
DE602006006861D1 (de) | Herstellung von polytrimethylenetherglykol und copolymeren davon | |
DE602004022010D1 (de) | Sicherheitsspritze | |
BRPI0418466B1 (pt) | conjunto de assentos de aeronave e aeronave. | |
DK1481084T3 (da) | Anvendelse af ribozymer til detektion af adventive stoffer | |
FI20040981A (fi) | Turvalaite | |
DE602005018064D1 (de) | Pressformer und dämpfungsring | |
SE0402477L (sv) | Värmeanläggning och uppvärmningsförfarande | |
ATA3402004A (de) | Kunstleder | |
DK1773451T3 (da) | Anvendelse af 7-t-butoxyiminomethylcamptothecin til behandling af uterine neoplasmer | |
FI20041385A (fi) | Symmetria-akselin määrittäminen | |
DK1592417T3 (da) | Kombinationen af antidiabetiske lægemidler |